Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 231 entries
Sorted by: Best Match Show Resources per page
Risks in estimating risk.

European heart journal

Graham IM, Cooney MT.
PMID: 24204012
Eur Heart J. 2014 Mar;35(9):537-9. doi: 10.1093/eurheartj/eht286. Epub 2013 Nov 07.

No abstract available.

Cite
Graham IM, Cooney MT. Risks in estimating risk. Eur Heart J. 2013;35(9):537-9doi: 10.1093/eurheartj/eht286.
Graham, I. M., & Cooney, M. T. (2014). Risks in estimating risk. European heart journal, 35(9), 537-9. https://doi.org/10.1093/eurheartj/eht286
Graham, Ian M, and Cooney, Marie-Therese. "Risks in estimating risk." European heart journal vol. 35,9 (2014): 537-9. doi: https://doi.org/10.1093/eurheartj/eht286
Graham IM, Cooney MT. Risks in estimating risk. Eur Heart J. 2014 Mar;35(9):537-9. doi: 10.1093/eurheartj/eht286. Epub 2013 Nov 07. PMID: 24204012.
Copy Download .nbib Format: NLM
Preface. Novel targets and drugs to prevent atherogenesis and its consequences.

European journal of pharmacology

Riksen NP, Rongen GA.
PMID: 26370897
Eur J Pharmacol. 2015 Sep 15;763:1-2. doi: 10.1016/j.ejphar.2015.08.042.

No abstract available.

Cite
Riksen NP, Rongen GA. Preface. Novel targets and drugs to prevent atherogenesis and its consequences. Eur J Pharmacol. 2015;763:1-2doi: 10.1016/j.ejphar.2015.08.042.
Riksen, N. P., & Rongen, G. A. (2015). Preface. Novel targets and drugs to prevent atherogenesis and its consequences. European journal of pharmacology, 7631-2. https://doi.org/10.1016/j.ejphar.2015.08.042
Riksen, Niels P, and Rongen, Gerard A. "Preface. Novel targets and drugs to prevent atherogenesis and its consequences." European journal of pharmacology vol. 763 (2015): 1-2. doi: https://doi.org/10.1016/j.ejphar.2015.08.042
Riksen NP, Rongen GA. Preface. Novel targets and drugs to prevent atherogenesis and its consequences. Eur J Pharmacol. 2015 Sep 15;763:1-2. doi: 10.1016/j.ejphar.2015.08.042. PMID: 26370897.
Copy Download .nbib Format: NLM
Parsing Atherosclerosis: The Unnatural History of Peripheral Artery Disease.

Circulation

Aronow HD, Beckman JA.
PMID: 27502907
Circulation. 2016 Aug 09;134(6):438-40. doi: 10.1161/CIRCULATIONAHA.116.022971.

No abstract available.

Cite
Aronow HD, Beckman JA. Parsing Atherosclerosis: The Unnatural History of Peripheral Artery Disease. Circulation. 2016;134(6):438-40doi: 10.1161/CIRCULATIONAHA.116.022971.
Aronow, H. D., & Beckman, J. A. (2016). Parsing Atherosclerosis: The Unnatural History of Peripheral Artery Disease. Circulation, 134(6), 438-40. https://doi.org/10.1161/CIRCULATIONAHA.116.022971
Aronow, Herbert D, and Beckman, Joshua A. "Parsing Atherosclerosis: The Unnatural History of Peripheral Artery Disease." Circulation vol. 134,6 (2016): 438-40. doi: https://doi.org/10.1161/CIRCULATIONAHA.116.022971
Aronow HD, Beckman JA. Parsing Atherosclerosis: The Unnatural History of Peripheral Artery Disease. Circulation. 2016 Aug 09;134(6):438-40. doi: 10.1161/CIRCULATIONAHA.116.022971. PMID: 27502907.
Copy Download .nbib Format: NLM
From the Editor: The Akira Endo Award. Foreword.

Journal of clinical lipidology

Brown WV.
PMID: 26228664
J Clin Lipidol. 2015 Jul-Aug;9(4):479-83. doi: 10.1016/j.jacl.2015.06.003. Epub 2015 Jun 16.

No abstract available.

Cite
Brown WV. From the Editor: The Akira Endo Award. Foreword. J Clin Lipidol. 2015;9(4):479-83doi: 10.1016/j.jacl.2015.06.003.
Brown, W. V. (2015). From the Editor: The Akira Endo Award. Foreword. Journal of clinical lipidology, 9(4), 479-83. https://doi.org/10.1016/j.jacl.2015.06.003
Brown, W Virgil. "From the Editor: The Akira Endo Award. Foreword." Journal of clinical lipidology vol. 9,4 (2015): 479-83. doi: https://doi.org/10.1016/j.jacl.2015.06.003
Brown WV. From the Editor: The Akira Endo Award. Foreword. J Clin Lipidol. 2015 Jul-Aug;9(4):479-83. doi: 10.1016/j.jacl.2015.06.003. Epub 2015 Jun 16. PMID: 26228664.
Copy Download .nbib Format: NLM
Are We Ready for Routine 'Subclinical' Atherosclerosis Screening? Not Yet….

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery

Abbott AL.
PMID: 27374815
Eur J Vasc Endovasc Surg. 2016 Sep;52(3):313-6. doi: 10.1016/j.ejvs.2016.06.002. Epub 2016 Jun 30.

No abstract available.

Cite
Abbott AL. Are We Ready for Routine 'Subclinical' Atherosclerosis Screening? Not Yet…. Eur J Vasc Endovasc Surg. 2016;52(3):313-6doi: 10.1016/j.ejvs.2016.06.002.
Abbott, A. L. (2016). Are We Ready for Routine 'Subclinical' Atherosclerosis Screening? Not Yet…. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 52(3), 313-6. https://doi.org/10.1016/j.ejvs.2016.06.002
Abbott, A L. "Are We Ready for Routine 'Subclinical' Atherosclerosis Screening? Not Yet…." European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery vol. 52,3 (2016): 313-6. doi: https://doi.org/10.1016/j.ejvs.2016.06.002
Abbott AL. Are We Ready for Routine 'Subclinical' Atherosclerosis Screening? Not Yet…. Eur J Vasc Endovasc Surg. 2016 Sep;52(3):313-6. doi: 10.1016/j.ejvs.2016.06.002. Epub 2016 Jun 30. PMID: 27374815.
Copy Download .nbib Format: NLM
Diet, atherosclerosis, and helmintic infection in Tsimane.

Lancet (London, England)

Masterson EE, Leonard WR, Hujoel PP.
PMID: 29115238
Lancet. 2017 Nov 04;390(10107):2034-2035. doi: 10.1016/S0140-6736(17)31945-1.

No abstract available.

Cite
Masterson EE, Leonard WR, Hujoel PP. Diet, atherosclerosis, and helmintic infection in Tsimane. Lancet. 2017;390(10107):2034-2035doi: 10.1016/S0140-6736(17)31945-1.
Masterson, E. E., Leonard, W. R., & Hujoel, P. P. (2017). Diet, atherosclerosis, and helmintic infection in Tsimane. Lancet (London, England), 390(10107), 2034-2035. https://doi.org/10.1016/S0140-6736(17)31945-1
Masterson, Erin E, et al. "Diet, atherosclerosis, and helmintic infection in Tsimane." Lancet (London, England) vol. 390,10107 (2017): 2034-2035. doi: https://doi.org/10.1016/S0140-6736(17)31945-1
Masterson EE, Leonard WR, Hujoel PP. Diet, atherosclerosis, and helmintic infection in Tsimane. Lancet. 2017 Nov 04;390(10107):2034-2035. doi: 10.1016/S0140-6736(17)31945-1. PMID: 29115238.
Copy Download .nbib Format: NLM
Diet, atherosclerosis, and helmintic infection in Tsimane.

Lancet (London, England)

Howland RH.
PMID: 29115239
Lancet. 2017 Nov 04;390(10107):2034. doi: 10.1016/S0140-6736(17)31955-4.

No abstract available.

Cite
Howland RH. Diet, atherosclerosis, and helmintic infection in Tsimane. Lancet. 2017;390(10107):2034doi: 10.1016/S0140-6736(17)31955-4.
Howland, R. H. (2017). Diet, atherosclerosis, and helmintic infection in Tsimane. Lancet (London, England), 390(10107), 2034. https://doi.org/10.1016/S0140-6736(17)31955-4
Howland, Robert H. "Diet, atherosclerosis, and helmintic infection in Tsimane." Lancet (London, England) vol. 390,10107 (2017): 2034. doi: https://doi.org/10.1016/S0140-6736(17)31955-4
Howland RH. Diet, atherosclerosis, and helmintic infection in Tsimane. Lancet. 2017 Nov 04;390(10107):2034. doi: 10.1016/S0140-6736(17)31955-4. PMID: 29115239.
Copy Download .nbib Format: NLM
Inhibition of atherosclerosis by angiotensin II type 1 receptor antagonists.

American journal of cardiovascular drugs : drugs, devices, and other interventions

Peters S.
PMID: 23609531
Am J Cardiovasc Drugs. 2013 Aug;13(4):221-4. doi: 10.1007/s40256-013-0017-4.

No abstract available.

Cite
Peters S. Inhibition of atherosclerosis by angiotensin II type 1 receptor antagonists. Am J Cardiovasc Drugs. 2013;13(4):221-4doi: 10.1007/s40256-013-0017-4.
Peters, S. (2013). Inhibition of atherosclerosis by angiotensin II type 1 receptor antagonists. American journal of cardiovascular drugs : drugs, devices, and other interventions, 13(4), 221-4. https://doi.org/10.1007/s40256-013-0017-4
Peters, Stefan. "Inhibition of atherosclerosis by angiotensin II type 1 receptor antagonists." American journal of cardiovascular drugs : drugs, devices, and other interventions vol. 13,4 (2013): 221-4. doi: https://doi.org/10.1007/s40256-013-0017-4
Peters S. Inhibition of atherosclerosis by angiotensin II type 1 receptor antagonists. Am J Cardiovasc Drugs. 2013 Aug;13(4):221-4. doi: 10.1007/s40256-013-0017-4. PMID: 23609531.
Copy Download .nbib Format: NLM
Interleukin-17 in atherosclerosis: Still a long road ahead.

International journal of cardiology

Ladeiras-Lopes R, Koenig W.
PMID: 26478522
Int J Cardiol. 2016 Jan 01;202:932. doi: 10.1016/j.ijcard.2015.10.060. Epub 2015 Oct 09.

No abstract available.

Cite
Ladeiras-Lopes R, Koenig W. Interleukin-17 in atherosclerosis: Still a long road ahead. Int J Cardiol. 2015;202:932doi: 10.1016/j.ijcard.2015.10.060.
Ladeiras-Lopes, R., & Koenig, W. (2016). Interleukin-17 in atherosclerosis: Still a long road ahead. International journal of cardiology, 202932. https://doi.org/10.1016/j.ijcard.2015.10.060
Ladeiras-Lopes, Ricardo, and Koenig, Wolfgang. "Interleukin-17 in atherosclerosis: Still a long road ahead." International journal of cardiology vol. 202 (2016): 932. doi: https://doi.org/10.1016/j.ijcard.2015.10.060
Ladeiras-Lopes R, Koenig W. Interleukin-17 in atherosclerosis: Still a long road ahead. Int J Cardiol. 2016 Jan 01;202:932. doi: 10.1016/j.ijcard.2015.10.060. Epub 2015 Oct 09. PMID: 26478522.
Copy Download .nbib Format: NLM
Cyanotic congenital heart disease and atherosclerosis.

Heart (British Cardiac Society)

Tarp JB, Jensen AS, Engstrøm T, Holstein-Rathlou NH, Søndergaard L.
PMID: 28259844
Heart. 2017 Jun;103(12):897-900. doi: 10.1136/heartjnl-2016-311012. Epub 2017 Mar 04.

Improved treatment options in paediatric cardiology and congenital heart surgery have resulted in an ageing population of patients with cyanotic congenital heart disease (CCHD). The risk of acquired heart disease such as atherosclerosis increases with age.Previous studies have speculated...

Cite
Tarp JB, Jensen AS, Engstrøm T, et al. Cyanotic congenital heart disease and atherosclerosis. Heart. 2017;103(12):897-900doi: 10.1136/heartjnl-2016-311012.
Tarp, J. B., Jensen, A. S., Engstrøm, T., Holstein-Rathlou, N. H., & Søndergaard, L. (2017). Cyanotic congenital heart disease and atherosclerosis. Heart (British Cardiac Society), 103(12), 897-900. https://doi.org/10.1136/heartjnl-2016-311012
Tarp, Julie Bjerre, et al. "Cyanotic congenital heart disease and atherosclerosis." Heart (British Cardiac Society) vol. 103,12 (2017): 897-900. doi: https://doi.org/10.1136/heartjnl-2016-311012
Tarp JB, Jensen AS, Engstrøm T, Holstein-Rathlou NH, Søndergaard L. Cyanotic congenital heart disease and atherosclerosis. Heart. 2017 Jun;103(12):897-900. doi: 10.1136/heartjnl-2016-311012. Epub 2017 Mar 04. PMID: 28259844.
Copy Download .nbib Format: NLM
Is Coronary Atherosclerosis One Disease or Many? Setting Realistic Expectations for Precision Medicine.

Circulation

Khera AV, Kathiresan S.
PMID: 28289003
Circulation. 2017 Mar 14;135(11):1005-1007. doi: 10.1161/CIRCULATIONAHA.116.026479.

No abstract available.

Cite
Khera AV, Kathiresan S. Is Coronary Atherosclerosis One Disease or Many? Setting Realistic Expectations for Precision Medicine. Circulation. 2017;135(11):1005-1007doi: 10.1161/CIRCULATIONAHA.116.026479.
Khera, A. V., & Kathiresan, S. (2017). Is Coronary Atherosclerosis One Disease or Many? Setting Realistic Expectations for Precision Medicine. Circulation, 135(11), 1005-1007. https://doi.org/10.1161/CIRCULATIONAHA.116.026479
Khera, Amit V, and Kathiresan, Sekar. "Is Coronary Atherosclerosis One Disease or Many? Setting Realistic Expectations for Precision Medicine." Circulation vol. 135,11 (2017): 1005-1007. doi: https://doi.org/10.1161/CIRCULATIONAHA.116.026479
Khera AV, Kathiresan S. Is Coronary Atherosclerosis One Disease or Many? Setting Realistic Expectations for Precision Medicine. Circulation. 2017 Mar 14;135(11):1005-1007. doi: 10.1161/CIRCULATIONAHA.116.026479. PMID: 28289003; PMCID: PMC5395046.
Copy Download .nbib Format: NLM
Atherosclerosis: Recent trials, new targets and future directions.

International journal of cardiology

Ladeiras-Lopes R, Agewall S, Tawakol A, Staels B, Stein E, Mentz RJ, Leite-Moreira A, Zannad F, Koenig W.
PMID: 26002254
Int J Cardiol. 2015 Aug 01;192:72-81. doi: 10.1016/j.ijcard.2015.05.013. Epub 2015 May 08.

Mortality from cardiovascular diseases (CVD) represents the primary cause of death worldwide. Prevention or treatment of atherosclerosis and its clinical sequelae is a central goal in the management of patients with established vascular disease or those at high-risk for...

Cite
Ladeiras-Lopes R, Agewall S, Tawakol A, et al. Atherosclerosis: Recent trials, new targets and future directions. Int J Cardiol. 2015;192:72-81doi: 10.1016/j.ijcard.2015.05.013.
Ladeiras-Lopes, R., Agewall, S., Tawakol, A., Staels, B., Stein, E., Mentz, R. J., Leite-Moreira, A., Zannad, F., & Koenig, W. (2015). Atherosclerosis: Recent trials, new targets and future directions. International journal of cardiology, 19272-81. https://doi.org/10.1016/j.ijcard.2015.05.013
Ladeiras-Lopes, Ricardo, et al. "Atherosclerosis: Recent trials, new targets and future directions." International journal of cardiology vol. 192 (2015): 72-81. doi: https://doi.org/10.1016/j.ijcard.2015.05.013
Ladeiras-Lopes R, Agewall S, Tawakol A, Staels B, Stein E, Mentz RJ, Leite-Moreira A, Zannad F, Koenig W. Atherosclerosis: Recent trials, new targets and future directions. Int J Cardiol. 2015 Aug 01;192:72-81. doi: 10.1016/j.ijcard.2015.05.013. Epub 2015 May 08. PMID: 26002254.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 231 entries